Jorge A. Garcia, MD, FACP, chairperson of the Oncologic
Drugs Advisory Committee (ODAC) for the US Food & Drug Administration,
shared insight on the recent ODAC meeting where members determined that
olaparib plus abiraterone as an upfront treatment for mCRPC should be
restricted to patients with BRCA mutations. Dr. Garcia is a medical oncologist
at the University Hospitals Seidman Cancer Center and is the center’s George
& Edith Richman Distinguished Scientist Chair, as well as Chief of their
Solid Tumor Oncology division.
